PharmaVibe

PharmaSources
  • 0.0 (0)
  • BUSINESS
  • UPDATED WEEKLY
PharmaVibe

Listen to the official pharma podcast hosted by PharmaSources and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas at: https://www.pharmasources.com/pharmavibe. Stay in tune with the industry experts, thought leaders, innovators, and leading decision-makers. For more market information from PharmaSources: Visit PharmaSources.com: https://www.pharmasources.com/ On Linkedin: https://www.linkedin.com/company/pharmasources/ On Facebook: https://www.facebook.com/Pharmasources On Twitter: https://twitter.com/Pharmachina365

  1. 11/22/2022

    The First Domestically Developed JAK Inhibitor Ivarmacitinib is Expected to Be First Marketed in China for Autoimmune System Diseases

    The online platform for CPHI & PMEC China is fully live now! The online event will be live for 54 days to help you connect for an extended period of time. Looking back on this week’s pharma news, BeiGene’s new indication for Zanubrutinib was approved in the EU while TopAlliance submitted a marketing application for the anti-PD-1 monoclonal antibody Toripalimab in the EU. The most noteworthy in the R&D section is Hengrui’s JAK inhibitor Phase III clinical success, making it be expected to become the first product made in China in the field of autoimmune system diseases.

    16 min

  2. 11/15/2022

    NMPA Nod Gives YL-Pharma First Highly Selective PI3Kδ Inhibitor Marketing Approval in China

    This week, the first highly selective PI3Kδ inhibitor in China, linperlisib of YL-Pharma, was approved for marketing. Multiple positive results have been released from several clinical trials, but GSK announced that the Phase III superiority trial of its BCMA ADC combined with pomalidomide in the treatment of relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival (PFS). Jumpcan Pharmaceutical entered into a cooperation agreement with Newsoara and obtained the development rights of two innovative drugs. More pharma news of this week worthy of attention covers topics on drug review, R&D, and business.

    14 min

  3. 11/08/2022

    The Marketing Approval of Luye Pharma’s First-in-class Anti-depressant Drug in China

    This week, Toludesvenlafaxine Hydrochloride Extended-Release Tablets, a kind of first-in-class anti-depressant drug developed by the Chinese company Luye Pharma, was approved for marketing. In terms of R&D, the phase III clinical research of PCSK9 Monoclonal Antibody developed by Akeso met the endpoints and was planned to apply for marketing. In terms of business, SonnetBio and Janssen, a subsidiary of Johnson & Johnson, reached a cooperation agreement on three candidate products.

    14 min

  4. 11/01/2022

    The Marketing Declaration of HAISCO’s Novel Analgesic for Diabetic Peripheral Neuralgia Treatment

    This week, the marketing application of HAISCO’s first-in-class HSK16149 Capsule was submitted, presumably for the treatment of diabetic peripheral neuralgia. Several clinical trials achieved positive results, while Alpine Immune terminated two clinical trials of davoceticept due to the death of patients. More pharma news of this week worthy of attention covers topics on drug review, R&D, and Listing.

    13 min

  5. 10/25/2022

    The Marketing Approval for GSK’s Two-Drug HIV Treatment in China

    The two most noteworthy news were the approval of the two-drug HIV therapy developed by GSK for marketing in China and the submission of the marketing application for Zevorcabtagene Autoleucel injection of CARsgen, which is the second BCMA CAR-T product to be declared for marketing in China.

    12 min

  6. 10/18/2022

    China’s NMPA Nod Gives Hua Medicine First GKA Approval in Diabetes

    The news review of this week is from October 8 to 14, covering a total of 25 pieces of information in 3 sections, i.e. drug review and approval, R&D, and business.

    14 min

  7. 10/08/2022

    The Marketing Declaration of The First JAK inhibitor made in China

    This week, in terms of drug review and approval, three pieces of news are particularly worthy of attention: Humanwell Healthcare’s first generic drug of oxycodone hydrochloride sustained release tablets were approved for marketing; Zelgen Biopharmaceuticals’ Jaktinib, the first JAK inhibitor made in China, was declared for marketing; and LEGN.US’ Cilta-cel, a BCMA CAR-T cell therapy, was approved in Japan. In terms of R&D, Eisai and Biogen announced positive results from the Phase III trial of Lecanemab to treat Alzheimer’s disease (AD); There is also some news worthy of attention in terms of business and policy.

    14 min

  8. 09/27/2022

    InnoCare Completes IPO on the STAR Market of the Shanghai Stock Exchange in China

    This week, in China, Nanjing Biosnwill Pharma’s Class 2.2 new drug Edaravone Sublingual Tablets and Yichang Humanwell’s Class 3 generic drug Clobazam Tablets have been approved by the NMPA for marketing. Meanwhile, new indications have been approved for both Junshi Biosciences’ Toripalimab and AstraZeneca’s Olaparib Tablets; New progress with the EMA and FDA approvals has been achieved for some popular drugs. For example, Roche’s bispecific antibody ophthalmic drug Faricimab has been approved for marketing in the EU. Although there has been nothing new in R&D during the week, on the business side, Chiatai Tianqing entered into a collaboration agreement with Inventiva for the development of lanifibranor, a pan-PPAR agonist. Besides, InnoCare Pharma was successfully listed on the STAR. Other pharma news collected this week features 25 pieces of information covering topics on drug review, R&D, business and listing.

    14 min
See All (13)

    About

    Listen to the official pharma podcast hosted by PharmaSources and sense the heartbeat of the industry through news stories, key conferences, and in-depth interviews encompassing an array of specialties, sectors, and areas at: https://www.pharmasources.com/pharmavibe. Stay in tune with the industry experts, thought leaders, innovators, and leading decision-makers. For more market information from PharmaSources: Visit PharmaSources.com: https://www.pharmasources.com/ On Linkedin: https://www.linkedin.com/company/pharmasources/ On Facebook: https://www.facebook.com/Pharmasources On Twitter: https://twitter.com/Pharmachina365

    Information

    • Creator
      PharmaSources
    • Years Active
      2K
    • Episodes
      13
    • Rating
      Clean
    • Copyright
      © Copyright 2022 All rights reserved.
    • Show Website
      PharmaVibe

    Content Restricted

    This episode can’t be played on the web in your country or region.

    To listen to explicit episodes, sign in.

    Stay up to date with this show

    Sign in or sign up to follow shows, save episodes, and get the latest updates.
    Select a country or region

    Africa, Middle East, and India

    Asia Pacific

    Europe

    Latin America and the Caribbean

    The United States and Canada